Single nucleotide polymorphisms (SNPs) in the genes that encode the cytochrome P450 (CYP) drug metabolizing enzymes and drug transporters have been reported to influence antiretroviral drug pharmacokinetics. Although primarily metabolized by CYP2B6 and -3A, efavirenz (EFV) and lopinavir/ritonavir (LPV/r) are substrates of P-glycoprotein and the solute carrier organic (SLCO) anion transporter, respectively. We investigated the association between SNPs and efavirenz (EFV) or lopinavir/ritonavir (LPV/r) concentrations in Chinese children infected with the human immunodeficiency virus (HIV). Genotyping was performed on CYP2B6 516G?T, -1459C?T, and -983T?C, ABCB1 3435C?T, and SLCO1B1 521T?C in 229 HIV-infected Chinese pediatric patients (age range 4.0 to 17.5 yrs). Plasma concentrations of EFV and LPV/r were measured using validated high-performance liquid chromatography coupled with the mass spectrum method among 39 and 69 children who received EFV-and LPV/r-containing regimens, respectively. The frequencies of CYP2B6 516G?T in the study participants were 71%, 25%, and 4% for the G/G, G/T, and T/T genotypes, respectively. Among the children under therapeutic drug monitoring, 21% and 39% experienced EFV and LPV concentrations, respectively, above the upper threshold of the therapeutic window. CYP2B6 516G?T was significantly associated with EFV concentrations (p<0.001). Older children (older than 10 yrs) were more likely to have significantly higher EFV concentrations than the younger ones (p=0.0314). CYP2B6 genotyping and EFV concentration monitoring may help optimize antiretroviral therapy in pediatric patients who initiate an EFV-based regimen.
infected with the human immunodeficiency virus (HIV-1). [1] [2] [3] By the end of 2014, a total of 5275 HIV-infected Chinese children had received antiretroviral therapy (ART) through this program. Unlike the standard ART regimens in the United States or Europe for HIV-infected pediatric patients, the currently preferred treatment options in China include efavirenz-(EFV) and lopinavir/ritonavir (LPV/r)-based regimens in line with the World Health Organization (WHO) guidelines, commonly used in the lowand middle-income countries. [4] [5] [6] Clinical, immunologic, and virologic outcomes of ART in this program were reported previously. 7 Despite a high response rate to ART (~75%), a considerable number of children with HIV still experience treatment failure and drug toxicity. 8, 9 Whereas the exposure-response relationship, particularly toxicity, has been suggested for certain antiretroviral agents in adult patients, it remains largely unclear among HIV-infected children. 10 The process of puberty and growth has a substantial impact on drug metabolism. Therefore, it has been considered a practical approach to perform therapeutic drug monitoring and subsequent dosage adjustment to optimize the antiretroviral treatment in children. 11 Several single nucleotide polymorphisms (SNPs) in the genes encoding drug transporters and cytochrome P450 (CYP) metabolizing enzymes were shown to affect gene expression and/or protein activity, as well as related pharmacokinetics. 12 EFV and LPV/r are the most important agents as a part of the preferred regimens recommended by the WHO and Chinese pediatric HIV treatment guideline. 13 Although primarily metabolized by CYP2B6 and -3A, EFV and LPV/r are substrates of P-glycoprotein and the solute carrier organic (SLCO) anion transporter, respectively. CYP2B6 516 G?T and 983T?C were significantly associated with plasma concentrations of EFV that is primarily metabolized by CYP2B6.
14-17 P-glycoprotein, encoded by ATP Binding Cassette Subfamily B Member 1 (ABCB1), was suggested in drug transport, but previous studies investigating the association of ABCB1 3435C?T and drug concentrations were inconclusive.
18-21 SLCO1B1 (also known as OAT1B1) encodes organic anion transporting polypeptide 1B1, and several previous studies indicated an association of SLCO1B1 521T?C with plasma LPV/r exposure. [22] [23] [24] The primary objective of the present study was to investigate effects of the genotypes on antiretroviral drug concentrations in Chinese children infected with HIV-1.
Materials and Methods

Study Design and Participants
This was a single-center cohort analysis of 229 HIV-infected Chinese children receiving long-term care at the Chinese Center for Disease Control Clinic in Shangcai County, Henan Province, between 2010 and 2013. This site was selected because of its long history of providing ART to the largest cohort of HIV-infected children, accounting for nearly 20% in China. Among the 229 patients, 21 were treatment naive, and 208 received a standard ART regimen including nevirapine, EFV, or LPV/r in combination with lamivudine and zidovudine, stavudine, or abacavir. The standardized dosage was based on subject weight bands as defined in the China Free ART Manual. 13 After treatment initiation, patients were followed up every 3 months for 6 months, with whole blood samples (5 ml) collected at each visit for CD4+ T cell count and clinical laboratory tests to monitor efficacy and toxicity. Plasma samples for drug concentration monitoring were collected from patients who received EFV-or LPV/r-based regimens at least 1 mo after ART initiation at the steady state and during the follow-up visits. The samples were collected before the patients received their morning dose. The resulting concentrations represented trough (Ctrough) for LPV/r and mid-dosing interval for EFV, given at bedtime without food.
All patients on EFV or LPV/r were selected for the drug concentration monitoring study. However, if they took their morning dose of LPV/r before the sample collection (19 patients) or received EFV with food or missed the dose at bedtime (2 patients), their samples were excluded from the analysis. Time since last dose was calculated based on the dosing history retrieved from the medical records. This study was approved by the institutional review board at the National Center for AIDS/STD Control and Prevention in China. Both patients and parents provided informed consent.
Genotyping
DNA was extracted from the whole blood by phenol-chloroform extraction using the commercially available Qiagen QIAamp Blood Mini Kit according to the manufacturer's protocol (Qiagen, Hilden, Germany). Genotypic analyses were performed on the following SNPs: CYP2B6 516G?T (Exon4, rs3745274), -1459C?T (Exon9, rs3211371), and -983T?C (exon7,
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PHARMACOTHERAPY Volume 37, Number 9, 2017 rs28399499), ABCB1 3435 C?T (Exon 26, rs1045642) and SLCO1B1 521T?C (rs4149056) by polymerase chain reaction, followed by ABI PRISM SNaPshot Multiplex Kit and GeneMapper v.4.0 (Applied Biosystems, Foster City, CA).
Antiretroviral Drug Concentration Measurement
Plasma concentrations of EFV, LPV, and ritonavir (RTV) were measured by a validated HPLC-MS method. 25 Inter-and intra-assay variation ranged between 1% and 10%. Linear ranges were 50-10,000 ng/ml for EFV and 10-10,000 ng/ml for LPV and RTV. For patients with multiple measurements, mean concentrations of multiple measurements were used in the final analysis. The therapeutic window used in the present study for EFV was at a mid-interval concentration range of 1000-4000 ng/ml 26, 27 and 1000-10,000 ng/ml for LPV 28, 29 to ensure efficacy and minimize the risk of toxicity. Absolute CD4+ T cell counts were analyzed by FACS Calibur (BD Biosciences, San Jose, CA).
Statistical Analysis
Clinical characteristics including age, sex, route of transmission, CD4+ T cell count, plasma HIV-1 RNA, and treatment duration were described by medians and interquartile range (IQR) or proportions. Allelic frequencies were calculated as number of alleles divided by all alleles in the population. The v 2 test was used to compare allelic frequencies and genotypic frequencies. The effect of potential influencing factors, such as sex, age (10 yrs or older vs younger than 10 yrs), ABCB1 3435 C?T, CYP2B6 516G?T, and SLCO1B1 521T?C, on plasma concentrations of EFV, LPV, or RTV were examined using the nonparametric Wilcoxon signed rank test. The selection of the 10-year-old break point was primarily based on findings from the ARROW trial that demonstrated age-dependent viral suppression in pediatric patients such that long-term suppression was better with EFV in children younger than 10 years and with nevirapine in those older than 10 years. 30 A multivariable linear regression was performed for multiple factors with p values less than 0.10. Post hoc pairwise comparisons of drug concentrations and genotype groups, as well as adjustment for significant factors such as age and sex, were performed for confirmation. A p value less than 0.05 was considered statistically significant. Statistical analyses were performed using SAS v.9.1 (SAS Institute, Cary, NC).
Results
Demographic Characteristics
A total of 229 participants were enrolled in the study with an age range from 4.0-17.5 years of age, of whom 39 and 69 received EFV-or LPV/r-based regimens, respectively, and had plasma concentrations monitored. Table 1 lists the clinical characteristics of these participants.
Genotype Frequencies
Genotypes for CYP2B6 516G?T, -1459C?T, -983T?C, ABCB1 3435C?T, and SLCO1B1 521T?C were obtained in 229 patients. The genotype data from the study population did not significantly deviate from the Hardy-Weinberg equilibrium. As shown in Table 2 , homozygous variants of CYP2B6 983 T?C and -1459C?T were not identified in this study population. The allelic frequencies are also summarized in Table 2 , with a T allele frequency of 16.8% in CYP2B6 516G?T.
Interindividual (CV inter ) and Intraindividual (CV intra ) Variability
The weight-based median dosage was 12.2 (IQR 10.8-13.4) mg/kg and 10.5 (IQR 9.2-11.8) mg/kg for EFV and LPV, respectively. Time since last dose was 13.3 AE 0.7 hours for EFV and 13.4 AE 0.7 hours for LPV/r. We collected 93 blood samples from 39 patients receiving EFVbased regimens. Only one patient experienced low EFV concentration (978.5 ng/ml), whereas eight patients (21%) experienced EFV concentration greater than 4000 ng/ml. We collected 143 blood samples from 69 patients receiving the LPV/r-containing regimen. No sample was below 1000 ng/ ml, whereas LPV concentrations from 27 patients (39%) were above 10,000 ng/ml. Table S1 summarizes the intra-and interindividual variabilities. EFV demonstrated the highest interindividual variability (109%) but the lowest intraindividual variability (12%), whereas LPV had the lowest interindividual variability (45%) and RTV had the highest intraindividual variability (38%).
Associations between Genotypes and Drug Concentrations
The effect of genotypes (CYP2B6 516G?T, ABCB1 3435C?T, and SLCO1B1 521 T?C), sex, and age on EFV, LPV, and RTV concentrations were included in the univariable analysis with the nonparametric Wilcoxon signed rank test. Because of the low frequencies of CYP2B6 983T?C and -1459C?T variants, these SNPs were excluded from the association analysis. A significant association was identified between CYP2B6 516 G?T and EFV concentrations (p=0.0009) ( Table 3 ). The median EFV concentration (IQR) was 2322 ng/ml (1932-2761 ng/ ml) for GG (26 patients), 3394 ng/ml (2760-4442 ng/ml) for GT (12 patients), and 23,668 ng/ml for TT (1 patient) (Figure 1 ). The univariable analysis identified significant effects of sex, age, and CYP2B6 516 G?T on EFV concentrations (p<0.05; Table 3 ). An association between ABCB1 3435C?T and EFV concentrations was suggested (p=0.0827) without statistical significance. CYP2B6 516 G?T remained significant in the multivariable analysis (p<0.0001), but age (p=0.1299) and sex (p=0.2798) did not. Post hoc pairwise comparisons of EFV concentrations and genotype groups confirmed significantly higher EFV concentrations in GT and TT than those in GG after adjusting for age and sex. All of these factors had no significant effects on the concentrations of LPV or RTV in the univariable analysis (p>0.05; Table 3 ), even though a higher median LPV concentration was observed with CT (8627 ng/ml) in comparison with that with TT (6952 ng/ml), suggesting an association of SLCO1B1 521 T?C and LPV concentrations without reaching statistical significance (p=0.0918).
Discussion
To our knowledge, this is the first study to evaluate effects of genotypes on antiretroviral drug concentrations in HIV-infected Chinese children. Despite a number of previous studies in sub-Saharan African countries, 31, 32 limited data are currently available on antiretroviral pharmacogenomics in pediatric Asian populations.
The current dosing recommendations of antiretroviral agents in China for pediatric patients are based on body weight bands in line with the WHO guidelines. 13, 33 Wide interpatient differences in antiretroviral drug concentrations have been associated with fixeddose regimens. 34 For example, whereas 95% of an American adolescent cohort had adequate EFV concentrations, 35 subtherapeutic EFV concentrations were reported in 40% and 64% of pediatric patients in South Africa and Germany, respectively. 36, 37 A therapeutic drug monitoring study in adult patients receiving EFV also reported 37% below the therapeutic window but 6% above the upper threshold. 29 In our study, almost all of the measured EFV and LPV concentrations (except one EFV concentration) were above the lower threshold. However, 20.5% and 39.1% of the patients experienced high EFV and LPV concentrations above the upper threshold, suggesting the current EFV and LPV/r dosage recommendation might provide sufficient therapeutic control of HIV infection for most Chinese children, but overdose might occur in a considerable portion of these pediatric patients. The recent randomized double-blind, placebo-controlled noninferiority ENCORE1 study showed that EFV at a reduced 400 mg/day dose remained noninferior to a 600 mg/day dose in treatment-naive adult patients. 38, 39 In addition, numerous reports demonstrated safety and effects of EFV dose reduction to prevent discontinuations as a result of EFV-related adverse drug reactions. 40, 41 The new WHO treatment guideline has therefore recommended EFV 400 mg/day as the alternative first-line regimen in adults and adolescents older than 12 years. 4 Our findings suggested that EFV dose reduction might be needed for pediatric patients in China.
The present study demonstrated low intrapatient variability for EFV (12%), which might be due to its convenient once/day dosing and long half-life, and high interpatient variability (109%), likely associated with the variation in EFV metabolism. A number of SNPs in CYP2B6, including 516G?T, 983T?C, and 1459C?T, were associated with plasma EFV concentrations. 42 CYP2B6 983T?C and 1459C?T were excluded from the analysis because of their low frequencies in the Chinese population, particularly people with Han nationalities. A significant association was revealed among Chinese pediatric patients between CYP2B6 516G?T and EFV plasma concentrations in the present study, which was consistent with the previous results in both pediatric and adult populations. 15, 43 The frequency of variant T allele varies among different ethnicities with 14%, 15%, 26%, and 49% in Japanese, Korean, white, and African populations, respectively. 44, 45 The T allele frequency was 16.8% in the present study, similar to that observed in Japanese, Koreans, and Han Chinese (21%) but lower than 34.5% reported in 507 southern Chinese from Hong Kong. 46 In addition, the frequency of the 516TT genotype (4.4%) in this study population, mainly with Han nationality and from central China, was significantly lower than that reported in southern Chinese (23.1%), suggesting regional differences in CYP2B6 516G?T frequencies in China. Because the CYP2B6 516G?T genotype was significantly associated with EFV metabolism and nearly 20% of patients having EFV concentrations above the upper threshold, a genotypebased EFV dosage adjustment might be needed to optimize treatment outcomes and avoid concentration-related adverse drug effects.
Age might be an influencing factor for drug metabolism because hepatic enzyme activity is significantly higher in children compared with adults. 43, 47 Consistent with findings in our study, older children (older than 10 yrs) had significantly higher EFV concentrations than the younger ones (p=0.0314) in the univariate analysis, but not in the multivariable analysis, suggesting a more important role of CYP2B6 in determining EFV pharmacokinetics. Sex appeared to be the other confounding factor for EFV concentrations where significantly higher concentrations were observed among males than females in the univariable analysis (p=0.0325) but not in the multivariable analysis. This might reflect the sex differences in hepatic expression of CYP2B6 where significantly higher expression of CYP2B6 (more than 1.7-fold) and activity (more than 1.6-fold) were reported in females in comparison with males. 48 The Chinese HIV/AIDS Treatment Guidelines recommend LPV/r as the second-line treatment for pediatric patients with HIV-1 infection. 13 The present study found nearly a third (25.9%) of the LPV concentrations higher than the upper threshold of the therapeutic window (10,000 ng/ml), and high intrapatient variability of LPV/r among Chinese pediatric patients, possibly due to a twice/day dosing regimen and a relatively wide range of sampling time, ranging from 11.5-15 hours. Recent studies demonstrated that SLCO1B1 521T?C was significantly associated with lower LPV clearance and higher concentrations in adults. 23, 49 A prospective cohort study in 50 children (4-18 yrs of age) on stable antiretroviral therapy with LPV/r indicated a significant association between SLCO1B1 521T?C 
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PHARMACOTHERAPY Volume 37, Number 9, 2017 and increased LPV exposure, but not with viral load. 50 The present study revealed a low frequency of SLCO1B1 521CC genotype (less than 1%) in Chinese children and 21.4% heterogeneous 521TC genotype. A trend for high LPV concentrations among 521C allele carriers was observed without statistical significance (p=0.0918). Further studies to confirm the clinical importance of SLCO1B1 polymorphisms in LPV pharmacokinetics might be warranted.
The present study had certain limitations. This was a single-center cross-sectional retrospective study design, and all of the study participates were from the Han nationality. Therefore, the genetic profiles, particularly the frequencies of the SNPs, might not represent the characteristics of the Chinese population. Due to its small sample size, analyses of associations between antiretroviral drug concentrations and adverse effects or virologic response were not performed. Although a significant difference in EFV concentrations was noted among genotypes (Table 3) , much of the concentration data appeared to be driven by only one subject with the homogeneous mutant genotype of CYP2B6 516G?T (Figure 1 ). Thus the relationship between genotypes and drug concentrations would be further reinforced if more study subjects with the TT genotype and high EFV concentrations were identified. Despite these limitations, the findings from this study have provided additional evidence to support genotype-based EFV dose adjustment as a part of precision medicine for not only Chinese, but also Asian, children with HIV infection.
